Safety and Efficacy of CD33-Targeted CAR-NK Cell Therapy for Relapsed/Refractory AML: Preclinical Evaluation and Phase I Trial

Investigators developed a new CAR construct that targets CD33 and modified natural killer cells, specifically eliminating acute myeloid leukemia cells while reducing severe side effects on stem cells.